Dominari Holdings Inc. DOMH

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
57/100
Moderate

About Dominari Holdings Inc.

Dominari Holdings Inc., through its subsidiaries, engages in wealth management, investment banking, sales and trading, and asset management activities in the United States and internationally. The company operates through two segments: Dominari Financial and Legacy AIkido. It offers full-service brokerage services, including exchange-traded and over-the-counter corporate equity and debt securities, money market instruments, exchange-traded options, municipal bonds, mutual funds, exchange-traded … Full DOMH analysis →

Competitive advantage assessment

Key strengths

  • Cost Leadership Position Operating margin at 77.7th percentile with strong OpEx control demonstrates cost leadership.
  • Strong Interest Coverage & Conservative Leverage Debt serviceability is strong (score 0.87), with robust interest coverage.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 13.1th percentile with high volatility suggests weak pricing power or commoditized products.
  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.23), suggesting weak customer stickiness.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
18

Where DOMH ranks in Biotechnology

Dominari Holdings Inc. ranks #142 of 713 scored companies in Biotechnology by moat score — the top 20%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

Moat scores for companies ranked near DOMH in Biotechnology
# Company Moat score Rating
138 Conduit Pharmaceuticals Inc. CDT 58/100 Moderate
139 Phathom Pharmaceuticals, Inc. PHAT 58/100 Moderate
140 Foghorn Therapeutics Inc. FHTX 57/100 Moderate
141 Fortrea Holdings Inc. FTRE 57/100 Moderate
142 Dominari Holdings Inc. DOMH 57/100 Moderate
143 Zevra Therapeutics, Inc. ZVRA 57/100 Moderate
144 C4 Therapeutics, Inc. CCCC 57/100 Moderate
145 Grace Therapeutics, Inc. GRCE 57/100 Moderate
146 Nektar Therapeutics NKTR 57/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How DOMH scores on the Corporate Default defenses

Pricing Power

Score 18 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 89 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 64 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 45 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 74 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 66 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding DOMH's moat

What is Dominari Holdings Inc.'s moat score?

Dominari Holdings Inc. (DOMH) scores 57 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #142 of 713 scored companies in Biotechnology, the top 20%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Cost Advantage (89/100) and its weakest is Pricing Power (18/100).

How does Dominari Holdings Inc. compare with other Biotechnology companies?

Dominari Holdings Inc. ranks #142 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Fortrea Holdings Inc. (FTRE) at 57 just above it and Zevra Therapeutics, Inc. (ZVRA) at 57 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Dominari Holdings Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Dominari Holdings Inc.?

The Corporate Default template measures 6 defenses, and DOMH scores: Pricing Power (18), Cost Advantage (89), Customer Stickiness (64), Capital Efficiency (45), Resilience (74), Scale & Market Position (66). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000